Swarm chondrosarcoma: A continued resource for chondroblastic-like extracellular matrix and chondrosarcoma biology research

Connective Tissue Research

Volumn 54, Issue 4-5, 2013, Pages 252-259

  Stevens, Jeff W ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Chondrocyte like; Extracellular matrix; Proteoglycan therapeutics; Rat chondrosarcoma

Indexed keywords

CATHEPSIN K; COLLAGEN TYPE 2; COLLAGENASE; CONNECTIVE TISSUE GROWTH FACTOR; DISPASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCOCORTICOID; GLYPICAN; GLYPICAN 1; GLYPICAN 3; GROWTH HORMONE; HYALURONIDASE; INSULIN; SYNDECAN; THYMOSIN BETA4; TRANSFORMING GROWTH FACTOR BETA2; TRYPSIN;

ADRENAL GLAND; CARCINOGENESIS; CARTILAGE CELL; CELL ADHESION; CELL ISOLATION; CELL PROLIFERATION; CELL SURFACE; CHONDROSARCOMA; CYTOGENETICS; CYTOLOGY; DISEASE COURSE; ENCHONDRAL OSSIFICATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLYCOSYLATION; GOLGI COMPLEX; HUMAN; HYPOPHYSIS; LUNG METASTASIS; LYMPHOCYTE; MARKER CHROMOSOME; MICROENVIRONMENT; NONHUMAN; ONCOGENE C FOS; PHYSICAL DISEASE BY BODY FUNCTION; PROTEOGLYCAN SYNTHESIS; REVIEW; ROUGH ENDOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SIMPSON GOLABI BEHMEL SYNDROME; SWARM CHONDROSARCOMA; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHONDROSARCOMA; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PROTEOGLYCANS; RATS; TUMOR CELLS, CULTURED;

EID: 84884245028     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.3109/03008207.2013.806913     Document Type: Review

References (57)

1. Choi HU, Meyer K, Swarm R. Mucopolysaccharide and proteinpolysaccharide of a transplantable rat chondrosarcoma. Proc Natl Acad Sci USA 1971;68: 877-9. Epub 1971/05/01.
2. Maibenco HC, Krehbiel RH, Nelson D. Transplantable osteogenic tumor in the rat. Cancer Res 1967;27: 362-6.
3. Salomon DS, Paglia LM, Verbruggen L. Hormone-dependent growth of a rat chondrosarcoma in vivo. Cancer Res 1979;39: 4387-95.
4. Kenan S, Steiner GC. Experimental transplantation of the Swarm rat chondrosarcoma into bone: radiological and pathological studies. J Orthop Res 1991;9: 445-51.
5. Kimura JH, Hardingham TE, Hascall VC, Solursh M. Biosynthesis of proteoglycans and their assembly into aggregates in cultures of chondrocytes from the Swarm rat chondrosarcoma. J Biol Chem 1979;254: 2600-9.
6. King KB, Kimura JH. The establishment and characterization of an immortal cell line with a stable chondrocytic phenotype. J Cell Biochem 2003;89: 992-1004.
7. Hauselmann HJ, Masuda K, Hunziker EB, Neidhart M, Mok SS, Michel BA, Thonar EJ. Adult human chondrocytes cultured in alginate form a matrix similar to native human articular cartilage. Am J Physiol 1996;271:C742-52.
8. Kimura JH, Thonar EJ, Hascall VC, Reiner A, Poole AR. Identification of core protein, an intermediate in proteoglycan biosynthesis in cultured chondrocytes from the Swarm rat chondrosarcoma. J Biol Chem 1981;256: 7890-7.
9. Warner LR, Brown RJ, Yingst SM, Oxford JT. Isoform-specific heparan sulfate binding within the amino-terminal noncollagenous domain of collagen alpha1(XI). J Biol Chem 2006;281: 39507-16.
10. Smith BD, Martin GR, Miller EJ, Dorfman A, Swarm R. Nature of the collagen synthesized by a transplanted chondrosarcoma. Arch Biochem Biophys 1975;166: 181-6.
11. Saito S, Zeck B, Inerot S, Kuettner KE, Kimura JH. A long term culture of cells from Swarm rat chondrosarcoma in suspension after alginate preculture. Keio J Med 1988;37: 282-98.
12. Fernandes RJ, Schmid TM, Harkey MA, Eyre DR. Incomplete processing of type II procollagen by a rat chondrosarcoma cell line. Eur J Biochem 1997;247: 620-4.
13. Fernandes RJ, Schmid TM, Eyre DR. Assembly of collagen types II, IX and XI into nascent hetero-fibrils by a rat chondrocyte cell line. Eur J Biochem 2003;270: 3243-50.
14. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 1999;13: 1361-6.
15. Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson LM, Bryja V, Kozubik A, Wilcox WR. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PloS One 2008;3:e3961.
16. Stevens JW, Patil SR, Jordan DK, Kimura JH, Morcuende JA. Cytogenetics of swarm rat chondrosarcoma. Iowa Orthop J 2005; 25: 135-40.
17. Grimaud E, Damiens C, Rousselle AV, Passuti N, Heymann D, Gouin F. Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. Histol Histopathol 2002;17: 1103-11.
18. Hamm CA, Stevens JW, Xie H, Vanin EF, Morcuende JA, Abdulkawy H, Seftor EA, Sredni ST, Bischof JM, Wang D, Malchenko S, Bonaldo Mde F, Casavant TL, Hendrix MJ, Soares MB. Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors. BMC Cancer 2010; 10:471.
19. Czitrom AA, Pritzker KP, Langer F, Gross AE, Luk SC. Virusinduced osteosarcoma in rats. J Bone Joint Surg Am 1976;58: 303-8.
20. Enneking WF, Flynn L. Effects of VX-2 carcinoma implanted in bone in rabbits. Cancer Res 1968;28: 1007-13.
21. Friedlaender GE, Mitchell MS. A virally induced osteosarcoma in rats. A model for immunological studies of human osteosarcoma. J Bone Joint Surg Am 1976;58: 295-302.
22. Aigner T, Muller S, Neureiter D, Illstrup DM, Kirchner T, Bjornsson J. Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas. Cancer 2002;94: 2273-81.
23. Soderstrom M, Ekfors T, Bohling T, Aho A, Aro HT, Vuorio E. Cysteine proteinases in chondrosarcomas. Matrix Biol 2001;19: 717-25.
24. Soderstrom M, Aro HT, Ahonen M, Johansson N, Aho A, Ekfors T, Bohling T, Kahari VM, Vuorio E. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. APMIS 2001;109: 305-15.
25. Aigner T. Towards a new understanding and classification of chondrogenic neoplasias of the skeleton - biochemistry and cell biology of chondrosarcoma and its variants. Virchows Arch 2002; 441: 219-30.
26. O'Neal LW, Ackerman LV. Chondrosarcoma of bone. Cancer 1952; 5: 551-77.
27. Rosenthal DI, Schiller AL, Mankin HJ. Chondrosarcoma: correlation of radiological and histological grade. Radiology 1984;150: 21-6.
28. Laplantine E, Rossi F, Sahni M, Basilico C, Cobrinik D. FGF signaling targets the pRb-related p107 and p130 proteins to induce chondrocyte growth arrest. J Cell Biol 2002;158: 741-50.
29. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 2003;95: 1674-80.
30. Yosimichi G, Nakanishi T, Nishida T, Hattori T, Takano-Yamamoto T, Takigawa M. CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK). Eur J Biochem 2001;268: 6058-65.
31. Masi L, Malentacchi C, Campanacci D, Franchi A. Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone. Virchows Arch 2002;440: 491-7.
32. Fransson LA, Belting M, Cheng F, Jonsson M, Mani K, Sandgren S. Novel aspects of glypican glycobiology. Cell Mol Life Sci 2004;61: 1016-24.
33. Haupt LM, Murali S, Mun FK, Teplyuk N, Mei LF, Stein GS, van Wijnen AJ, Nurcombe V, Cool SM. The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. J Cell Physiol 2009;220: 780-91.
34. Tan TW, Yang WH, Lin YT, Hsu SF, Li TM, Kao ST, Chen WC, Fong YC, Tang CH. Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1- dependent pathway in human chondrosarcoma cells. Carcinogenesis 2009;30: 258-68.
35. Papachristou DJ, Papachristou GI, Papaefthimiou OA, Agnantis NJ, Basdra EK, Papavassiliou AG. The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology 2005;47: 565-74.
36. Chen TL, Stevens JW, Cole WG, Hecht JT, Vertel BM. Cell-type specific trafficking of expressed mutant COMP in a cell culture model for PSACH. Matrix Biol 2004;23: 433-44.
37. Posey KL, Liu P, Wang HR, Veerisetty AC, Alcorn JL, Hecht JT. RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein. PloS One 2010;5:e10302.
38. Zang J, Plaas AHK, Kimura JH. A clonal cell line derived for the Swarm rat chondrosarcoma is defective in expression on the sulfate transporter gene for diastrophic dysplasia. Trans Orthop Res 1999;24:398.
39. Solute carrier family 26 (sulfate transporter), member 2, SLC26A2. Availabale at: http://www.omin.org/entry/606718.
40. Esko JD, Rostand KS, Weinke JL. Tumor formation dependent on proteoglycan biosynthesis. Science 1988;241: 1092-6.
41. Fernandes RJ, Hirohata S, Engle JM, Colige A, Cohn DH, Eyre DR, Apte SS. Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. J Biol Chem 2001;276: 31502-9.
42. Ozaki T, Lindner N, Hillmann A, Rodl R, Blasius S, Winkelmann W. Influence of intralesional surgery on treatment outcome of chondrosarcoma. Cancer 1996;77: 1292-7.
43. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet 2003; 143: 1-31.
44. Hamm CA, Xie H, Costa FF, Vanin EF, Seftor EA, Sredni ST, Bischof J, Wang D, Bonaldo MF, Hendrix MJ, Soares MB. Global demethylation of rat chondrosarcoma cells after treatment with 5- aza-20-deoxycytidine results in increased tumorigenicity. PloS One 2009;4:e8340: 1-13.
45. Peyrode C, Weber V, David E, Vidal A, Auzeloux P, Communal Y, Dauplat MM, Besse S, Gouin F, Heymann D, Chezal JM, Redini F, Miot-Noirault E. Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies. Invest New Drugs 2012;30: 1782-90.
46. Schonthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol 2013;85: 653-66.
47. Meyers CD, Tannock LR, Wight TN, Chait A. Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. J Lipid Res 2003;44: 2152-60.
48. Oegema Jr TR, Parzych SM. Effect of the retinoic acid analog Ro 11-1430 on proteoglycans of swarm rat chondrosarcoma. J Natl Cancer Inst 1981;67: 99-106.
49. Lyon M, Gallagher JT. Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol 1998;17: 485-93.
50. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de Kier Joffe EB. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol 2008;23: 1333-40.
51. Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005;16: 205-13.
52. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125: 89-97.
53. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64: 2418-23.
54. Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA 2013;110:E1083-91.
55. Belting M, Borsig L, Fuster MM, Brown JR, Persson L, Fransson LA, Esko JD. Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci USA 2002;99: 371-6.
56. Fernandez IS, Cuevas P, Angulo J, Lopez-Navajas P, Canales- Mayordomo A, Gonzalez-Corrochano R, Lozano RM, Valverde S, Jimenez-Barbero J, Romero A, Gimenez-Gallego G. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem 2010;285: 11714-29.
57. Bovee JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010;10: 481-8.